Literature DB >> 29436707

The molecular pathology of cancer: from pan-genomics to post-genomics.

David G Huntsman1, Marc Ladanyi2.   

Abstract

As the cancer genomics of most major cancer types have been comprehensively catalogued over the past decade through a variety of national and international efforts, the delineation of cancer subtypes has been refined, and our understanding of critical cancer drivers and of the potentially targetable vulnerabilities that they create has grown tremendously. The 2018 Annual Review Issue of the Journal of Pathology provides in-depth assessments of how these pan-genomic approaches have enabled advances in cancer classification, targeted therapy selection, and assessment of cancer progression, all of which are now genomically informed, using several cancer types as examples. Beyond these areas of by now conventional pan-genomic tumour analysis, there are also reviews of diverse 'post-genomic' areas, such as the analysis of circulating free tumour DNA in plasma, concurrent germline cancer predisposition profiling in the setting of apparently sporadic cancer, genetic alterations in epigenetic control and DNA repair, proteomics of tumour heterogeneity, computational pathology, and the roles of the cellular stress response and the microbiome in human cancers. As we are able to derive more and more biologically useful information from diverse human biospecimens, these many advances are informing and transforming the practice of cancer pathology.
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  cancer genomics; molecular pathology; neoplasia

Mesh:

Substances:

Year:  2018        PMID: 29436707     DOI: 10.1002/path.5057

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

Review 1.  Why should radiation oncology do translational research? [corrected].

Authors:  Rut Cañas; Isabel Linares; Ferran Guedea; Miguel Ángel Berenguer
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-12

2.  DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334.

Authors:  Dapeng Sun; Xiaojie Gan; Lei Liu; Yuan Yang; Dongyang Ding; Wen Li; Junyao Jiang; Wenbin Ding; Linghao Zhao; Guojun Hou; Jian Yu; Jie Wang; Fu Yang; Shengxian Yuan; Weiping Zhou
Journal:  Cell Death Dis       Date:  2022-05-09       Impact factor: 9.685

3.  Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer.

Authors:  D Merino; T S Weber; A Serrano; F Vaillant; K Liu; B Pal; L Di Stefano; J Schreuder; D Lin; Y Chen; M L Asselin-Labat; T N Schumacher; D Cameron; G K Smyth; A T Papenfuss; G J Lindeman; J E Visvader; S H Naik
Journal:  Nat Commun       Date:  2019-02-15       Impact factor: 14.919

4.  Cancer Classification at the Crossroads.

Authors:  Antonino Carbone
Journal:  Cancers (Basel)       Date:  2020-04-15       Impact factor: 6.639

Review 5.  Adaptive response of resistant cancer cells to chemotherapy.

Authors:  Yi-Jye Chern; Isabella T Tai
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

Review 6.  Subclonal heterogeneity and evolution in breast cancer.

Authors:  Ioanna Mavrommati; Flora Johnson; Gloria V Echeverria; Rachael Natrajan
Journal:  NPJ Breast Cancer       Date:  2021-12-21

7.  Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.

Authors:  Ruiting Ye; Han Zeng; Zhaopei Liu; Kaifeng Jin; Chunnan Liu; Sen Yan; Yanze Yu; Runze You; Hongyi Zhang; Yuan Chang; Yiwei Wang; Li Liu; Yu Zhu; Jiejie Xu; Le Xu; Zewei Wang
Journal:  Cancer Immunol Immunother       Date:  2021-06-21       Impact factor: 6.968

8.  Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.

Authors:  Lisa Quetel; Clément Meiller; Jean-Baptiste Assié; Yuna Blum; Sandrine Imbeaud; François Montagne; Robin Tranchant; Julien de Wolf; Stefano Caruso; Marie-Christine Copin; Véronique Hofman; Laure Gibault; Cécile Badoual; Ecaterina Pintilie; Paul Hofman; Isabelle Monnet; Arnaud Scherpereel; Françoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Marie-Claude Jaurand; Didier Jean
Journal:  Mol Oncol       Date:  2020-03-10       Impact factor: 6.603

9.  Aberrant miRNAs expressed in HER-2 negative breast cancers patient.

Authors:  Cornelia Braicu; Lajos Raduly; Gabriela Morar-Bolba; Roxana Cojocneanu; Ancuta Jurj; Laura-Ancuta Pop; Valentina Pileczki; Cristina Ciocan; Alin Moldovan; Alexandru Irimie; Alexandru Eniu; Patriciu Achimas-Cadariu; Angelo Paradiso; Ioana Berindan-Neagoe
Journal:  J Exp Clin Cancer Res       Date:  2018-10-20

10.  Isobaric Tags for Relative and Absolute Quantitation in Proteomic Analysis of Potential Biomarkers in Invasive Cancer, Ductal Carcinoma In Situ, and Mammary Fibroadenoma.

Authors:  Hao Wu; Xian-Yu Zhang; Ming Niu; Fei-Feng Li; Song Gao; Wei Wei; Si-Wei Li; Xing-Da Zhang; Shu-Lin Liu; Da Pang
Journal:  Front Oncol       Date:  2020-10-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.